Literature DB >> 20930947

Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening.

Andrey A Kolokoltsov1, Mohammad F Saeed, Alexander N Freiberg, Michael R Holbrook, Robert A Davey.   

Abstract

While much progress has been made in developing drugs against a few prominent viruses such as HIV, few examples exist for emerging infectious agents. In some cases broad spectrum anti-viral drugs, such as ribavirin, are effective, but for some groups of viruses, these show little efficacy in animal models. Traditional methods focus on screening small molecule libraries to identify drugs that target virus factors, with the intention that side-effects to the host can be minimized. However, this greatly limits potential drug targets and virus genes can rapidly mutate to avoid drug action. Recent advances in siRNA gene targeting technologies have provided a powerful tool to specifically target and suppress the expression of cell genes. Since viruses are completely dependent upon host cell proteins for propagation, siRNA screening promises to reveal novel cell proteins and signaling pathways that may be viable targets for drug therapy regimens. Here we used an siRNA screening approach to identify gene products that play critical roles in Ebola virus infection. By gene cluster analysis, proteins in phosphatidylinositol-3-kinase and calcium/calmodulin kinase related networks were identified as important for Zaire Ebola virus infection and prioritized for further evaluation. Key roles of each were confirmed by testing available drugs specific for members of each pathway. Interestingly, both sets of proteins are also important in cancer and subject to intense investigation. Thus development of new drugs against these cancer targets may also prove useful in combating Ebola virus.

Entities:  

Year:  2009        PMID: 20930947      PMCID: PMC2949974          DOI: 10.1002/ddr.20303

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  42 in total

Review 1.  No false start for novel pseudotyped vectors.

Authors:  David Avram Sanders
Journal:  Curr Opin Biotechnol       Date:  2002-10       Impact factor: 9.740

2.  Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I.

Authors:  David W Carley
Journal:  IDrugs       Date:  2005-04

3.  Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.

Authors:  Deborah J Watson; Gary P Kobinger; Marco A Passini; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

4.  Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.

Authors:  Andrey A Kolokoltsov; Eryu Wang; Tonya M Colpitts; Scott C Weaver; Robert A Davey
Journal:  Am J Trop Med Hyg       Date:  2006-10       Impact factor: 2.345

Review 5.  Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor.

Authors:  Christopher Cianci; Nicholas Meanwell; Mark Krystal
Journal:  J Antimicrob Chemother       Date:  2005-01-28       Impact factor: 5.790

Review 6.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

7.  Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus.

Authors:  Andrey A Kolokoltsov; Drew Deniger; Elisa H Fleming; Norbert J Roberts; Jon M Karpilow; Robert A Davey
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

8.  Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.

Authors:  Susan E Morgan-Lappe; Lora A Tucker; Xiaoli Huang; Qian Zhang; Aparna V Sarthy; Dorothy Zakula; Lawrence Vernetti; Mark Schurdak; Jieyi Wang; Stephen W Fesik
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

9.  Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.

Authors:  Sonia Napravnik; Jessica R Keys; E Byrd Quinlivan; David A Wohl; Oksana V Mikeal; Joseph J Eron
Journal:  AIDS       Date:  2007-04-23       Impact factor: 4.177

10.  Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase.

Authors:  Marion S Freistadt; Joseph A Vaccaro; Karen E Eberle
Journal:  Virol J       Date:  2007-05-24       Impact factor: 4.099

View more
  22 in total

1.  Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

Authors:  Yasuteru Sakurai; Andrey A Kolokoltsov; Cheng-Chang Chen; Michael W Tidwell; William E Bauta; Norbert Klugbauer; Christian Grimm; Christian Wahl-Schott; Martin Biel; Robert A Davey
Journal:  Science       Date:  2015-02-27       Impact factor: 47.728

2.  Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.

Authors:  Jessica Y Rathbun; Magali E Droniou; Robert Damoiseaux; Kevin G Haworth; Jill E Henley; Colin M Exline; Hyeryun Choe; Paula M Cannon
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 3.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

4.  Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry.

Authors:  Maria V Yermolina; Jizhen Wang; Michael Caffrey; Lijun L Rong; Duncan J Wardrop
Journal:  J Med Chem       Date:  2011-01-04       Impact factor: 7.446

5.  Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.

Authors:  Julien Colas; Grazyna Faure; Emilie Saussereau; Stéphanie Trudel; Wael M Rabeh; Sara Bitam; Ida Chiara Guerrera; Janine Fritsch; Isabelle Sermet-Gaudelus; Noëlie Davezac; Franck Brouillard; Gergely L Lukacs; Harald Herrmann; Mario Ollero; Aleksander Edelman
Journal:  Hum Mol Genet       Date:  2011-10-28       Impact factor: 6.150

Review 6.  Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs.

Authors:  Stanford Schor; Shirit Einav
Journal:  DNA Cell Biol       Date:  2017-11-17       Impact factor: 3.311

7.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

Review 8.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06

Review 9.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

10.  Cellular factors implicated in filovirus entry.

Authors:  Suchita Bhattacharyya; Thomas J Hope
Journal:  Adv Virol       Date:  2013-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.